C-Mannosylation and O-Fucosylation of the Thrombospondin Type 1 Module*

Jan HofsteengeDagger, Kristin G. Huwiler§, Boris Macek||, Daniel Hess, Jack Lawler**, Deane F. Mosher§, and Jasna Peter-Katalinic

From the Friedrich Miescher-Institut, P. O. Box 2543, CH-4002 Basel, Switzerland, the § Departments of Medicine and Biomolecular Chemistry, University of Wisconsin, Madison, Wisconsin 53706, the  Institute for Medical Physics and Biophysics, University of Münster, Robert-Koch-Strasse 31, D-48149 Münster, Germany, and the ** Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston Massachusetts 02215

Received for publication, September 4, 2000, and in revised form, October 25, 2000



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Thrombospondin-1 (TSP-1) is a multidomain protein that has been implicated in cell adhesion, motility, and growth. Some of these functions have been localized to the three thrombospondin type 1 repeats (TSRs), modules of ~60 amino acids in length with conserved Cys and Trp residues. The Trp residues occur in WXXW patterns, which are the recognition motifs for protein C-mannosylation. This modification involves the attachment of an alpha -mannosyl residue to the C-2 atom of the first tryptophan. Analysis of human platelet TSP-1 revealed that Trp-368, -420, -423, and -480 are C-mannosylated. Mannosylation also occurred in recombinant, baculovirally expressed TSR modules from Sf9 and "High Five" cells, contradictory to earlier reports that such cells do not carry out this reaction. In the course of these studies it was appreciated that the TSRs in TSP-1 undergo a second form of unusual glycosylation. By using a novel mass spectrometric approach, it was found that Ser-377, Thr-432, and Thr-489 in the motif CSX(S/T)CG carry the O-linked disaccharide Glc-Fuc-O-Ser/Thr. This is the first protein in which such a disaccharide has been identified, although protein O-fucosylation is well described in epidermal growth factor-like modules. Both C- and O-glycosylations take place on residues that have been implicated in the interaction of TSP-1 with glycosaminoglycans or other cellular receptors.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Thrombospondin (TSP)1-1 is a large homotrimeric glycoprotein present in the alpha -granules of platelets (1). The 150-kDa monomer has a modular structure, with (from the N to C terminus) a heparin-binding domain, oligomerization domain, procollagen module, three type 1 repeats (TSRs, also called properdin modules), three EGF-like repeats, a calcium binding domain, and a globular C-terminal domain (2). It belongs to a protein family, which contains at least four other members (3). Upon activation with thrombin, for example, TSP-1 is secreted and binds to the surface of activated platelets, thereby promoting their aggregation (4). In addition, TSP-1 is incorporated into the fibrin network of the clot, where it influences the structure of the fibrin filaments (5, 6) and possibly their cleavage during fibrinolysis (7). TSP-1 is also secreted by growing cells and can interact with cellular surfaces, extracellular matrix, and soluble macromolecules. Roles for TSP-1 in a variety of processes, such as embryonic development, response to injury, tumor growth, and metastasis, angiogenesis, inflammation, growth factor activation, and neurite outgrowth, have been postulated (for reviews see Refs. 8-11).

The three TSR modules, which are found in TSP-1 and -2 but not in the other TSPs, are of particular importance to the present study. TSRs are ~60 amino acids in length and are characterized by conserved Cys, Trp, Ser, and Arg residues (9). Molecules that have been proposed to bind these modules in TSP-1 include fibrinogen/fibrin, CD36, heparan sulfate, other glycosaminoglycans and sulfatide, fibronectin, TGF-beta , laminin, and collagen VII (see Ref. 9 for a review). By using synthetic peptides, the amino acid sequence WSXW, which is present in all three TSRs, has been proposed to be involved in the binding of heparin as well as TGF-beta (12, 13). However, in studies using proteolytic fragments obtained from platelet TSP-1 (14), or recombinant TSRs from Sf9 cells (15), no heparin binding was observed at physiologic ionic strength. The amino acid sequence CSVTCG has been suggested to be a cell-binding site in the second and third TSR of TSP-1 (16-18). Although direct binding between the peptide YCSVTCG and Jurkat cells bearing CD36 has been reported (18), no increased binding of TSP-1 to COS cells expressing the receptor could be observed (19). At present the reasons for the discrepancies between different approaches remain unclear.

Post-translational modifications in TSP-1 could complicate the use of synthetic peptides or recombinant proteins. The sequence WXXW has recently been shown to be the recognition motif for a glycosyltransferase that attaches an alpha -mannopyranosyl residue to the C-2 position of the first Trp (20). We have shown that other proteins that contain TSRs, i.e. C6, C7, C8alpha , C8beta , C9, and properdin, are C-mannosylated on multiple Trp residues (21, 22). This form of protein glycosylation appears to be widespread in biology, since the C-mannosyltransferase activity has been found in mammals, birds, amphibians, and fish (23, 24), and tryptophan hexosylation has been found in insect cells (25).

Here we demonstrate that human platelet TSP-1 and recombinant TSRs expressed in various insect cells are C-mannosylated. These results increase the panel of proteins that are subject to C-mannosylation and the range of organisms able to catalyze this reaction. In the course of the mannosylation analyses, we discovered that all three TSRs contained an O-linked disaccharide (Glc-Fuc-O) on the homologous Thr or Ser residue in the sequence CXX(S/T)CG of the putative cell-binding site. This finding is the first report of this disaccharide in a protein and demonstrates that protein O-fucosylation is not restricted to EGF-like modules. Taken together the analyses show that the subtype of TSR found in TSP-1 is subject to two types of unusual glycosylations in a 10-residue stretch, to which several functions have been localized previously.


    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- Monosaccharide standards for HPAE-PAD analysis were obtained from Sigma. Human platelet TSP-1 was purified from the supernatant of thrombin-stimulated platelets as described previously (26). Recombinant TSR3 (see Fig. 1 for nomenclature of recombinant proteins) and TSR123 were expressed in Sf9 or High-Five cells using the vector pAcGP67P3.coco and pAcGP67P123.coco. These vectors are a modification of pAcGP67 (Invitrogen, Carlsbad, CA), in which modules of interest are placed between the signal sequence of baculovirus GP67 and a His tag. Details about construction of the vectors and protein purification have been published elsewhere (27). Recombinant TSR123 was also expressed in Drosophila S2 cells. A DNA fragment encoding all three TSRs of TSP-1 (amino acids 361-530) was prepared using human TSP-1 cDNA as a template and the forward primer 475htsp1f (GAT GAT CCC GGG GAC GAC TCT GCG GAC GAT GGC) and the reverse primer 476htsp1r (GAT ACC GGT AAT TGG ACA GTC CTG CTT G). The polymerase chain reaction product was cloned between the XmaI and the AgeI sites of the vector pMT/BiP/V5-HisA (Invitrogen, Carlsbad, CA). The recombinant protein included the vector-derived amino acid sequence RSPWG at the N terminus and TGHHHHHH at the C terminus. The fidelity of the polymerase chain reaction product was verified by nucleotide sequencing. The expression vector was cotransfected into Drosophila S2 cells with the selection vector pCoHYGRO according to the manufacturer's protocol (Invitrogen). Transfected cells were selected with hygromycin B, and the expression of recombinant peptide was monitored by Western blotting using the polyclonal antibody R3 that was raised against a fusion protein that contained all three TSRs of TSP-1 (4). For large scale preparation of recombinant protein, S2 cells were grown in serum-free media for 5 days. The culture supernatant was centrifuged to remove the cells and dialyzed against 20 mM sodium phosphate, pH 7.8, and 500 mM NaCl. The dialysate was applied to a column of ProBond resin (Invitrogen). The column was washed with 20 mM sodium phosphate, pH 7.8, and 500 mM NaCl followed by 20 mM sodium phosphate, pH 6.0, and 500 mM NaCl. The column was eluted stepwise with 20 mM sodium phosphate, pH 6.0, 500 mM NaCl containing 50, 200, or 500 mM imidazole. The protein eluting with 500 mM imidazole was dialyzed against 20 mM sodium phosphate, pH 7.0, and 500 mM NaCl, and 1% sucrose was added prior to storage.

Peptide Nomenclature-- The amino acid numbering of mature human TSP-1 has been used (2). Tryptic peptides have been numbered according to their occurrence in the mature polypeptide and have been labeled with the prefix "T." The following affixes were used to indicate subdigestions: chymotrypsin (Ch), endoproteinase AspN (D), aminopeptidase M (AMP), carboxypeptidase (CPase). Different subfragments have been numbered with arabic numbers according to their order in the parent peptide. In case of heterogeneity in a peptide, subforms have been indicated with Latin letters (e.g. T55a-Ch-1).

Isolation of Peptides-- Proteins were reduced and carboxamidomethylated as described (22) and cleaved with proteases at 37 °C. TSP-1 (0.4 or 5 mg) was digested twice with trypsin (1% w/w) in 50 mM NH4HCO3, pH 7.8, for 2 and 18 h, and relevant tryptic peptides were subfragmented with chymotrypsin (1% w/w) for 7 h. Recombinant TSR3 from Sf9 cells (70 µg in 400 µl of 50 mM Tris-HCl, pH 8.0) was digested twice with trypsin (1.5% w/w) for 2 and 4 h and subsequently with endoproteinase AspN (1.5% w/w) for 4 h. Peptides from recombinant TSR3 from High-Five cells were prepared in the same way, except that the tryptic peptide TSR3-H5-T55 was purified before cleavage with endoproteinase AspN. Recombinant protein TSR123 from Drosophila S2 cells (100 µg in 150 µl of 50 mM Tris-HCl, pH 8.0) and TSR123 from High-Five cells (130 µg or 2 mg in the same buffer) were cleaved twice with trypsin (1.5% w/w) for 2 h. Digests were fractionated by HPLC or LC-ESIMS using Vydac C8 and C18 columns essentially as described previously (22). If necessary, final purification of peptides was achieved by HPLC using 25 mM NH4 acetate, pH 6.0, containing 2 or 80% CH3CN as buffer A and B, respectively.

Analysis of C-Mannosylated Peptides-- Purified C-mannosylated peptides were examined by low energy CID tandem-MS experiments of the [M + 2H]2+ ions, using a Sciex API 300 mass spectrometer. The resolution of the first quadrupole was set to 1300 for the selected mass, whereas the third quadrupole was set at isotopic resolution over the entire mass range. Solid phase Edman degradation and identification of PTH-(C2-Man-)Trp were performed as described previously (22).

Nanospray Quadrupole-Time-of-Flight Mass Spectrometry of O-- Glycosylated Peptides---Nano-electrospray mass spectrometric analyses were performed on a quadrupole-time-of-flight (Q-TOF) mass spectrometer (Micromass, Manchester, UK) in the positive ion mode. Purified glycopeptides (~4-8 pmol/µl dissolved in methanol, 0.4% trifluoroacetic acid (1:1, v/v)), were loaded into homemade nanospray capillaries. In the CID tandem MS studies a precursor ion was selected in the quadrupole analyzer and partially fragmented in the hexapole collision cell, with the pressure of argon at 2.7 × 10-5 millibar and collision energy 20 eV. All masses were analyzed with an orthogonal time-of-flight analyzer equipped with a reflector, a microchannel plate detector, and a time-to-digital converter. Data acquisition was optimized to give the highest possible resolution and signal-to-noise ratio, even in the case of very low abundant signals. Analysis of the data was done with the Masslynx Windows NT PC data system. NaI and/or deglycosylated b and y ion series of the analyzed peptide were used for calibration. The mass accuracy of all measurements was within 0.2 m/z units.

Subfragmentation of O-Glycosylated Peptides-- Peptides T42-Ch-2, T49-Ch-2, and T55a-Ch-2 from platelet TSP-1 were subfractionated as follows. Digestions were performed at 37 °C with enzymes obtained from Roche Molecular Biochemicals. Where indicated, purification was achieved by LC-MS. The amounts of peptide were estimated from peak heights in HPLC experiments. The following buffers were used: 50 mM NH4HCO3, pH 7.3, for aminopeptidase M, the same buffer at pH 7.8 for CPase B, 50 mM NH4 acetate, pH 5.0, for CPase Y, 10 mM Tris-HCl, pH 8.0, for endoproteinase AspN, and 5 mM NH4HCO3 for subtilisin. Peptide T42-Ch-2 (200 pmol in 10 µl) was cleaved with 0.03 units of aminopeptidase M for 17 h, and the product was isolated. In a second experiment the purified product of the aminopeptidase digestion was further digested in 5 µl with CPase B (0.7 µg) for 2 h, dried, and cleaved with CPase Y (1 µg) for 44 h. Peptide T49-Ch-2 (100 pmol in 10 µl) was treated with aminopeptidase M in the same way. A second sample (200 pmol in 5 µl) was cleaved with endoproteinase AspN (220 ng) for 2 h. The purified product was then digested in 5 µl with 1 µg of CPase Y for 26 h. Peptide T55a-Ch-2 (200 pmol in 10 µl) was cleaved with subtilisin (200 ng) for 18 h. Purified fragment product in 10 µl was further cleaved with aminopeptidase M, as above. The cleavage of another 200 pmol in 5 µl with CPase B and Y was carried out as described for peptide T42-Ch-2.

The final products of these cleavages were analyzed in a nano-ESIMS experiment, monitoring neutral loss of 308 or 146 Da from either the [M + H]+ and/or [M + 2H]2+ ion, using the API 300 mass spectrometer. Their identity was verified in a low energy CID tandem-MS experiment, using the same apparatus. Methods for the MS analyses have previously been described (28). The corresponding peptides from recombinant TSR3 from Sf9 and High-Five cells were treated and analyzed in the same way.

Monosaccharide Building Block Analysis of O-Glycans with HPAE-PAD Chromatography-- Monosaccharide species from glycopeptides were obtained by acid hydrolysis in 2 M trifluoroacetic acid for 2 h at 100 °C. Building block analysis of released sugars was carried out on a DX 500 chromatography system (Dionex Corp., Sunnyvale, CA) using a CarboPacTM PA-1 column (4 × 250 mm). Oligosaccharides were detected using an ED40 electrochemical detector, with potentials of the gold electrode E1 = 0.05 V, E2 = 0.75 V, E3 = -0.15 V. The GP40 pump was run in isocratic mode, using 15% NaOH as eluent and flow rate of 1 ml/min. Monosaccharide standards (Fuc, Rha, Gal, Glc, and Man) were used for optimization and calibration.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Platelet TSP-1 Is C-Mannosylated on Trp-368, -420, -423, and -480-- Counting from the N terminus of mature human platelet TSP-1, the tryptic peptides T42, T49, and T55, originating from TSR-1, -2 and -3 respectively, contain potential C-mannosylation sites (Fig. 1). Reduced and carboxamidomethylated TSP-1 was cleaved with trypsin and fractionated by reversed phase LC-ESIMS (Fig. 2A). The MS data were extracted for the theoretical mass of each of these peptides, taking into account the possible presence of 0-3 hexosyl residues. This allowed the detection of modified peptides T42, T49, and T55a, as well as a minor amount of unmodified T55b (Fig. 2A). Nanospray ESIMSMS analysis of the impure peptides revealed that in all three peptides the third Trp residue in the WXXWXXW motif was unmodified (data not shown). This allowed the use of chymotrypsin to generate the N-terminal fragments of these peptides (affixed "Ch-1"), which contain the C-mannosylation sites, and their C-terminal fragments (affixed "Ch-2") (Fig. 2, B-D). Peptides T42-Ch-1, T49-Ch-1, and T55a-Ch-1 were purified to apparent homogeneity, as judged from the single amino acid sequence observed by Edman degradation.



View larger version (17K):
[in this window]
[in a new window]
 
Fig. 1.   Summary of the main proteolytic fragments of platelet TSP-1 and recombinant TSR modules used to study post-translational modifications. For the sake of clarity, the numbering of peptides and amino acid residues in TSP-1 has also been used for the recombinant proteins. Trp residues that are part of the C-mannosylation motif WXXW have been underlined. Sequences that differ between recombinant proteins and platelet TSP have been shown in italics. Parts of the molecules that are not relevant to this study have been indicated with dotted lines. The domains in TSP-1 have been indicated as follows: circled N, N-terminal domain; , procollagen homology domain; diamond , type 1 repeat; , type 2 repeat (EGF-like); open circle , type 3 repeat (calcium-binding); circled C, globular C-terminal domain.



View larger version (26K):
[in this window]
[in a new window]
 
Fig. 2.   Peptide mapping of TSP-1 from human platelets. A, reduced and carboxamidomethylated TSP-1 was cleaved with trypsin. The resulting peptides were fractionated by reversed phase LC-ESIMS, using a C8 column. Peptides T42 and T49 were found in modified form only, whereas peptide T55 occurred both in the modified (T55a) and unmodified form (T55b). B-D, elution profile of the chymotryptic digests of T42 (B), T49 (C), and T55a (D), obtained from the experiment shown in A. In all cases the affixed "-Ch-1" and "Ch-2" indicates the N- and C-terminal fragments, respectively (see Fig. 1 for peptide nomenclature). The insets show the ESIMS spectra of the C-terminal fragments, illustrating the dissociation of a 308-Da substituent.

Peptide T42-Ch-1, originating from the first TSR module, had a mass of 2230.0 Da, which was consistent with residues 355-371 containing one hexosyl residue. The substituent could be present at the Trp residues at positions 2, 11, or 14 of the peptide or it could be O-glycosidically linked to one of the hydroxy amino acids (Fig. 1). The latter could be excluded, because no 162-Da losses in MS or MSMS experiments, indicating O-linked hexose, were observed. It should be noted that under the MS conditions used, such phenomena were indeed observed in other peptides (see below). The ESIMSMS spectrum of peptide T42-Ch-1 is shown in Fig. 3A. The m/z values of ions b2-b8 all showed the Trp at position 2 of the peptide (Trp-355) to be unmodified. Modification of the Trp at positions 11 or 14 of the peptide (Trp-365 and -368, respectively) would result in MSMS spectra that differed in the ions b11-13 and y4-6. Five of the six ions that were expected for Trp-368 containing the 162-Da substituent were observed (Fig. 3A), but none of those indicating modification of Trp-365 were detected. In low energy CID tandem-MS, ions containing a (C2-Man-)Trp show a characteristic loss of 120 Da (22, 29, 30). The spectrum of T42-Ch-1 (Fig. 3A) exhibited this phenomenon for the parent, y5, y6, and b14 ions, thus providing evidence for the C-glycosidic linkage. Edman degradation yielded PTH-Trp in cycles 2 and 11, and in cycle 14 a PTH-derivative was observed, which comigrated exactly with PTH-(c2-Man-)Trp obtained from residues 5-10 of human RNase2 (Table I).





View larger version (67K):
[in this window]
[in a new window]
 
Fig. 3.   Low energy CID tandem-ESIMS of the C-mannosylated peptides from platelet TSP-1. Purified tryptic/chymotryptic peptides from the TSR modules of platelet TSP-1 were analyzed. A, T42-Ch-1; B, T49-Ch-1; C, T55a-Ch-1. The 120-Da loss, typical for aromatic C-glycosides, has been indicated with 120 and 60 for singly and doubly charged ions, respectively. Multiple losses of H2O have been indicated with asterisks. W#, C-mannosylated tryptophan; (Cam-)C, carboxamidomethylcysteine.


                              
View this table:
[in this window]
[in a new window]
 
Table I
Characterization of C-mannosylated (C-Man) and O-glycosylated peptides from TSP-1

Peptide T49-Ch-1 (1666.8 Da), from the second TSR module, was 324 Da heavier than expected from the cDNA sequence, suggesting the presence of two hexosyl residues. Fig. 3B shows its nanospray ESIMSMS. No losses indicating O-linked hexosyl residues were observed. The presence of the ions y5, y6, b6, and b8 strongly indicated that each of the Trp residues at positions 5 and 8 of the peptide (Trp-420 and-423, respectively) was carrying a hexosyl residue. Ions that would indicate that one of these residues was unmodified and the other modified with a 324-Da disaccharide were not detected. The characteristic 120-Da loss from the parent and b9 ions occurred twice, in agreement with two C-hexosylated residues in this peptide. Edman degradation of peptide T49-Ch-1 yielded PTH-(C2- Man-)Trp in cycles 5 and 8 (Table I).

The mass of peptide T55a-Ch-1 (1861.8 Da) suggested that it contained one hexosyl residue, which could be located on Trp residues at positions 9 or 12 of the peptide (Trp-477 and -480, respectively) or on Ser-481. However, no indication of an O-linked sugar was obtained. The two possible modifications of the Trp residues would yield different b9-b11 and y4-y6 ions. Five of the six ions that located the hexosyl residue to Trp-480 were observed (Fig. 3C), whereas only the ion at m/z 1287.7 would indicate that Trp-477 was modified. However, a more likely explanation for the latter would be loss of H2O from the (C-hexosylated) y10 ion (m/z 1305.7), since it was part of a continuous series of losses of H2O (* in Fig. 3C). The presence of a C-C linkage was concluded from the 120-Da losses from the parent, b12-b13, y5, y7-y10, and y12 ions. Edman degradation yielded PTH-Trp in cycle 9 and PTH-(C2-Man-)Trp in cycle 12 (Table I).

The minor amount of unmodified peptide T55b (3062 Da) was analyzed by nanospray ESIMSMS without further purification. The results (not shown) confirmed its identity and the absence of modification of its Trp residues.

The stoichiometry of C-mannosylation of the TSR modules of platelet TSP-1 was high. T42 and T49 were found in the C-mannosylated form only. The degree of modification of Trp-480 in peptide T55 was ~90%. Since both the modified and unmodified peptides comigrated with other peptides, this percentage could only be estimated from the area under the peak of [M + nH]n+ ions for n = 2 and 3, in the total ion current trace associated with the LC-ESIMS separation shown in Fig. 2A. A summary of these results is given in Fig. 4.



View larger version (18K):
[in this window]
[in a new window]
 
Fig. 4.   Summary of the C- and O-glycosylations of the TSR modules of platelet and recombinant TSP. C-Mannosylation has been indicated with closed hexagons, with the approximate percentage of modification below. Note that in TSR123-H5 C-hexosylation was demonstrated by ESIMS only, which does not establish the identity of the monosaccharide. In the other cases independent evidence for C-mannosylation was obtained by Edman degradation. The exact site of O-glycosylation and the identity of the sugars in TSR123-S2 and -H5 was not determined but was assumed to be the same as in the other proteins. The percentage modification was estimated by determining the area of relevant peaks in the UV trace at 214 nm of the LC-ESIMS separation (TSR123-S2, TSR123-H5, TSR3-Sf9, and TSR3-H5). Since in the case of the third TSR of TSP-1 the peak contained more than one peptide, the percentage modification could only be estimated from the areas of the [M + 2H]2+ and [M + 3H]3+ peaks in the total ion current trace of the LC-ESIMS separation.

Platelet TSP-1 Contains an O-Linked Disaccharide on Ser-377, Thr-432, and Thr-489-- The C-terminal, chymotryptic fragments of peptides T42, T49, and T55a were isolated in pure form (T42-Ch-2, T-49-Ch-2 and T55a-Ch-2; Fig. 2, B-D). The spectra of these peptides yielded masses that were 308 Da higher than predicted from the sequence. Characteristically, the theoretically predicted mass was observed as well (Fig. 2, B-D; insets). This was reminiscent of the behavior of O-linked saccharides, for which facile dissociation in MS and low energy CID tandem-MS experiments have been well documented (31, 32). Furthermore, the mass of 308 Da exactly fitted the sum of the masses of a deoxyhexosyl (146 Da) and a hexosyl residue (162 Da). These findings strongly suggested the presence of O-linked sugars in these peptides.

Peptide T42-Ch-2 contained five hydroxyamino acids that potentially could be O-glycosylated (Fig. 1). Four of these could be removed by digestion with aminopeptidase M. The resulting peptide, T42-Ch-2-AMP, still contained the 308-Da substituent (Table I). The Q-TOF tandem-MS of the doubly charged molecular ion of the peptide at m/z = 664.29 is shown in Fig. 5A. The observation of the B fragment ions of the HexdHex disaccharide at m/z = 309.12, deoxyhexose at m/z = 147.08, and hexose at m/z = 163.07, as well as the ions corresponding to their neutral loss of water provided evidence for the presence of the disaccharide moiety. The signals at m/z = 822.87 [M dHex + 2H]2+, 897.36 [b6 dHexHex]+, and 1153.44 [b8 dHexHex]+ strongly indicated that the disaccharide HexdHex is attached to Ser-377 through the dHex residue.





View larger version (91K):
[in this window]
[in a new window]
 
Fig. 5.   Low energy CID nano-ESI Q-TOF tandem MS sequencing of the glycopeptides T42-Ch-2-AMP (A), T49-Ch-2 (B), and T55-Ch-2 (C). For experimental conditions and assignment see the text.

Independent evidence for the site of modification was obtained by treating this peptide with CPase B followed by CPase Y. This yielded a peptide with a mass of 629.9 Da, having the sequence S(Cam)CG + 308 Da (Table I). Since the cysteine residue had been carboxymethylated, it could not carry the substituent, which therefore had to be present on the Ser residue (Table I).

In peptide T49-Ch-2 five potential glycosylation sites, i.e. Ser-427, Ser-428, Ser-430, Thr-432, and Thr-439 (Fig. 1), are present. The Q-TOF tandem-MS of the doubly charged molecular ion of the peptide at m/z = 903.88 is shown in Fig. 5B. The observation of the B fragment ions of the HexdHex disaccharide at m/z = 309.12, deoxyhexose at m/z = 147.06, and hexose m/z = 163.05, as well as the ions corresponding to their respective neutral losses of water, provided evidence for the presence of the disaccharide moiety. Its attachment to Thr-432 could be concluded from the observation of three singly charged glycosylated fragments: at m/z = 1286.59 [y9 HexdHex]+, 1472.54 [y11 HexdHex]+, and 1632.69 [y12 HexdHex]+. The signal at m/z = 822.87 [M dHex + 2H]2+ presented direct evidence for the HexdHex disaccharide attachment to Thr-432 through the dHex residue. No ions were detected that would indicate that either dHex, Hex, or the disaccharide Hex-dHex were attached to any of the remaining four potential glycosylation sites.

Aminopeptidase M treatment of peptide T49-Ch-2 yielded the peptide T(Cam-)CGDGVITR + 308 Da, whereas digestion with endoproteinase AspN followed by CPase B and Y, in a separate experiment, resulted in the peptide SS(Cam-)CSVT(Cam-)C + 308 Da (Table I). The two peptides only had the sequence -T(Cam-)C- in common, confirming that the substituent was present on the Thr residue.

In peptide T55-Ch-2 two possible O-glycosylation sites, i.e. Ser-487 and Thr-489, are present (Fig. 1). The Q-TOF tandem MS of the doubly charged ion of this peptide (m/z 845.01) is shown in Fig. 5C. The observation of the B fragment ions of the HexdHex disaccharide (m/z = 309.31) and the hexose (m/z = 163.24), as well as the ions corresponding to the neutral loss of water, provided evidence for the disaccharide. Its attachment to Thr-489 could be concluded from the observation of two out of four glycosylated peptide fragments, m/z = 952.50 [y8 dHex]+ and 1114.57 [y8 HexdHex]+. Furthermore, the signal at m/z = 952.50 strongly suggested that the HexdHex disaccharide was attached to Thr-489 through the dHex residue. It is important to note that no ions were detected, which would indicate that either dHex, Hex, or the disaccharide HexdHex was attached to Ser-487.

Peptide T55-Ch-2 yielded the peptide T(Cam-)CGGGQVK +308 Da (1113.2 Da) upon digestion with subtilisin followed by aminopeptidase M, and in a second experiment the peptide DI(Cam-)SVT(Cam-)C + 308 Da (1161.5 Da) was obtained after consecutive CPase B and Y digestion (Table I). The two fragments only had the sequence -T(Cam-)C- in common, confirming that the modification was present on Thr-489.

Fucose and Glucose Are the Major Constituents of O-Linked Glycans on TSP-1-- Results of HPAE-PAD analysis of monosaccharides released from O-glycosylated peptides of TSP-1 are summarized in Table II. Deoxyhexoses (Fuc and Rha) and hexoses (Glc, Gal, and Man), commonly occurring in O-linked oligosaccharides, were used as standards for instrument calibration. In all three peptides, very intense fucose and glucose peaks were observed (Fig. 6), which led to the conclusion that fucose and glucose are the major constituents of O-linked glycans on TSP-1. The glucose peak was sometimes followed by a much smaller peak with a retention time roughly the same as that of the mannose standard. Although the difference in retention time (30 s) and the shape of the peak suggested that it could not be assigned to mannose, additional analysis should be carried out. A summary of the analyses of the O-linked glycans is given in Fig. 4.


                              
View this table:
[in this window]
[in a new window]
 
Table II
Molar ratios of monosaccharides in O-linked glycans in TSP1 and TSR3
The molar amounts of fucose and glucose were estimated from the peak areas, relative to that of monosaccharide standards.



View larger version (15K):
[in this window]
[in a new window]
 
Fig. 6.   Typical HPAE-PAD chromatograms of monosaccharide standards (a) and monosaccharides (b) released from investigated O-glycopeptides, in this case TSR3-Sf9-T55-D-2a. Peaks corresponding to Fuc (peak 1) and Glc (peak 2) in the experimental sample are clearly visible. The origin of the 3rd peak is discussed in the text.

Recombinant TSR3 from Sf9 or High-Five Cells Are C-Mannosylated on Trp-480 and O-Glycosylated on Thr-489-- Sf9 cells infected with recombinant baculovirus carrying the construct encoding TSR3 (TSR3-Sf9) yielded protein that was heterogeneous with respect to its mass. A small amount of a species with the mass expected from the cDNA sequence (7250 Da, ~5% of the total) was detected by LC-ESIMS. In addition, four other species that had masses of 7396, 7412, 7558, and 7720 Da were found. Because the mass increments closely corresponded to that of integral numbers of dHex and Hex, the recombinant protein seemed to be glycosylated at multiple sites. A tryptic/endoproteinase AspN digest was fractionated by LC-ESIMS (Fig. 7), yielding multiple forms of both the N-terminal peptide, TSR3-Sf9-T55-D-1, as well as the C-terminal one, TSR3-Sf9-T55-D-2. All other observed peptides (Fig. 7, fractions 1, 2, 4, and 6) had masses as predicted from the cDNA sequence. Peptide TSR3-Sf9-T55-D-1a had a mass of 1758.8 Da, in agreement with the presence of one hexosyl residue. ESIMSMS and Edman degradation showed Trp-480 to be C-mannosylated, whereas the other Trp residues were unmodified (Table III). Peptide TSR3-Sf9-T55-D-1b had a mass, 1596.0 Da, in agreement with the theoretical value (Table III) and thus was unmodified. By integrating the areas under the relevant peaks, it could be estimated that Trp-480 was 55% C-mannosylated. Both peptides contain the sequence Asn-Gly, which is sensitive to deamidation at basic pH values. The deamidated forms of these peptides eluted ~0.4 min after the main peak (fractions 7a and 8a; Fig. 7) and had a mass that was 1 Da higher.



View larger version (11K):
[in this window]
[in a new window]
 
Fig. 7.   Peptide mapping of recombinant TSR3 from Sf9 cells. TSR3-Sf9 was cleaved with trypsin and subsequently with endoproteinase AspN. The peptides were fractionated by reversed phase LC-ESIMS, using a C8 column (see "Experimental Procedures"). Relevant fractions have been labeled with the name of the peptide (for nomenclature, see Fig. 1), whereas the remainder has been numbered in italics only.


                              
View this table:
[in this window]
[in a new window]
 
Table III
Characterization of C-mannosylated (C-Man) and O-glycosylated peptides from recombinant module TSR3 from Sf9 cells

Two major forms of the C-terminal peptide were isolated as follows: TSR3-Sf9-T55-D-2a, which was 308 Da heavier than expected from the cDNA sequence (Table III), and peptide TSR3-Sf9-T55-D-2b, which was 146 Da heavier. A small amount of a peptide with the mass expected from the cDNA sequence was detected in fraction 4, together with another peptide. Peptides TSR3-Sf9-T55-D-2a and -2b were examined by nanospray Q-TOF MS as described above for the peptides from platelet TSP-1. In addition, exopeptidase fragments were analyzed. The data (Table III) demonstrated that a disaccharide of the form Hex-dHex- was O-linked to Thr-489 in peptide TSR3-Sf9-T55-D-2a. A single dHex residue was present at the same position in peptide TSR3-Sf9-T55-D-2b. Integration of the peaks of these peptides (Fig. 7) showed that Thr-489 in TSR3 from Sf9 cells was 95% O-glycosylated. The ratio between mono- and disaccharide was ~1:1 (Fig. 4). In a separate experiment, tryptic peptides from this protein were analyzed without previous cleavage with endoproteinase AspN. This yielded six different TSR3-Sf9-T55 peptides, representing all possible combinations between C- and O-glycosylation at Trp-480 and Thr-489, respectively (data not shown). Taken together, these results explained the five forms of TSR3-Sf9, i.e. 7250 Da (no modifications), 7396 Da [+ (dHex-)Thr], 7412 Da [+(C2Man-)Trp], 7558 Da [+(C2-Man-)Trp and (dHex-)Thr, and +(HexdHex-)Thr], and 7720 Da [+(C-Man-)Trp and (HexdHex-)Thr]. Monosaccharide analysis (Table II) showed that only fucose could be positively identified in TSR3-Sf9-T55-D2b, whereas fucose and glucose were detected in TSR3-Sf9-D2a.

The same experiments, except for the monosaccharide analyses, were repeated with recombinant TSR3 from High-Five cells (TSR3-H5) (data not shown). The results revealed the same modifications, although at lower stoichiometries (Fig. 4).

Recombinant Modules TSR123 from S2 Cells Are Not C-Mannosylated but Are O-Glycosylated on Ser-377, Thr-432, and Thr-489-- Fig. 8A shows the part of the LC-ESIMS chromatogram containing the peptides with the C-mannosylation motifs and the O-glycosylations. All other observed major peptides had masses as predicted from the cDNA sequence. The MS data were extracted for the theoretical masses of TSR123-S2-T42, -T49, and -T55, including the C- and O-glycosylations described above. Only two species were detected for each of the three tryptic peptides, the unmodified form and one, which was 146 Da heavier (Table IV). No evidence for C-glycosylation was observed at all. To verify this, each of the tryptic peptides was cleaved with chymotrypsin. The results of an analytical LC-ESIMS experiments for each of the peptides is shown in Fig. 8, B-D. The peptides produced from the part of TSR123-S2-T42, -T49, and T55 containing the C-mannosylation motifs all had masses in agreement with those calculated from the DNA sequence (data not shown), and thus were unmodified. The C-terminal portions of these peptides, however, occurred in two forms, one having a mass that agreed with the cDNA sequence and one that was 146 Da heavier. The heavier peptides showed facile dissociation of the substituent in the LC-ESIMS experiment (Fig. 8, B-D), as was observed with the O-glycosylated peptides described above. The primary structure of these peptides was verified by nanospray ESIMSMS (Table IV), and the ratio of modified/unmodified peptides was estimated by integrating the area under their peaks in Fig. 8, B-D. Given the location of the O-linked sugars in platelet TSP-1 and recombinant TSR3-Sf9 and TSR3-H5, we assume that the dHex residues are located on Ser-377, Thr-432, and Thr-489. These results have been summarized in Fig. 4.



View larger version (18K):
[in this window]
[in a new window]
 
Fig. 8.   Peptide mapping of recombinant TSR123 from Drosophila S2 cells. A, the tryptic digest of TSR123-S2 was fractionated by LC-ESIMS on a C8 column. The part of the chromatogram containing the relevant peptides has been shown only. The arrows indicate the elution positions of the peptides that were 146 Da heavier than predicted, as detected by extraction of the MS data for their appropriate masses. The nomenclature of the peptides is indicated in Fig. 1. B-D, chymotryptic fragments obtained from peptide TSR123-S2-T42 (B), TSR123-S2-T49 (C), and TSR123-S2-T5 (D). Peptides whose masses agreed with those predicted from the cDNA sequence have been numbered in italics only. Those that were heterogeneous in mass have been indicated with their name in addition. The insets show the spectra of the chymotryptic fragments that were 146 Da heavier than expected from the cDNA sequence ([M + 2H]2+ ions). The dissociation of this substituent has been indicated with the difference in m/z value (dotted line).


                              
View this table:
[in this window]
[in a new window]
 
Table IV
Characterization of O-glycosylated peptides from recombinant TSR123 from Drosophila S2 cells

By using the same strategy, TSR123 from High-Five cells was examined as well (data not shown). In this case the first TSR was appreciably C-hexosylated, whereas the other two were less than 5% modified on Trp residues (Fig. 4). Small amounts of O-linked dHex and Hex-dHex were found in TSR1 and TSR2, whereas only the disaccharide was found on 30% of TSR3.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The results presented in this paper show that two sequences that have been implicated in several activities of human platelet TSP-1 do not occur as such but are covalently modified.

O-Glycosylation-- By using a novel, potent mass spectrometric approach that will be described in detail elsewhere,2 we demonstrated that the three TSRs in platelet TSP-1 carry the O-linked disaccharide Glc-Fuc-O-Ser/Thr in the sequence CSX(S/T)CG. This sequence is common to many TSR-containing proteins. In fact out of 88 TSRs examined, 63 had a Ser or Thr at the position preceding the Cys. Numerous functions have been assigned to this sequence, including cell adhesion (16, 33) and binding to the cell surface receptor CD36, an 88-kDa membrane protein that is expressed on many cells (18). This receptor mediates the in vitro inhibition of basic fibroblast growth factor-induced endothelial cell migration by TSP-1 (34) and is part of the signaling pathway utilized by TSP-1 in the inhibition of neovascularization in vivo (35). Direct binding between native TSRs and CD36 remains to be demonstrated, as does any effect of the O-linked disaccharide.

O-Linked fucose has been found in the EGF-like modules from a number of proteins (Table V) and has been assumed to be exclusive for this type of structure (36). The presence of the disaccharide Glc-Fuc-O-Ser/Thr in human platelet TSP-1 and the O-fucosylation of the proteinase inhibitor PMP-C from Locusta migratoria (37) show that this modification is more general. TSP-1 is the first identified protein that carries the O-linked disaccharide Glc-Fuc-O-Ser/Thr. Labeling experiments had provided evidence that Glc-beta 1,3-Fuc-alpha 1-O-Ser/Thr occurs in unidentified proteins from Chinese hamster ovary cells (38). In addition, it had been isolated as the amino acid fucoside from human urine (39, 40). O-Fucosylation of EGF-like modules occurs most likely in the Golgi (41), and the fucosyltransferase has been isolated (42). Based on primary structure comparisons, a consensus sequence for this modification in EGF-like modules (CXXGG(S/T)C) has been proposed (43). However, the O-fucosylation sites in TSP do not conform to this sequence (Table V). This raises the question as to whether the same fucosyltransferase is involved or whether more than one transferase exists. O-Linked fucose monosaccharide can be elongated into a di- or a tetrasaccharide in a protein-specific manner (Table V) (38). Supposedly, the elongating transferases recognize the fucose and as yet unidentified signals in the protein. Until now, the tetrasaccharide has exclusively been found in the EGF-like modules of factor IX and Notch (36, 44), whereas disaccharide has only been observed in TSRs (this paper).3 This raises the possibility that structural features specific for each of these modules lead to elongation of O-fucose into disaccharide and tetrasaccharide, respectively. Whether this is determined by the primary or the tertiary structure, as for other elongating glycosyltransferases (45), remains to be determined. In this context it should be noted that proper folding of the EGF-like module is required for fucosylation (42), strongly indicating that elongation also must take place after attainment of the three-dimensional structure.


                              
View this table:
[in this window]
[in a new window]
 
Table V
Comparison of sequences around glycosylation sites involving O-linked fucose

The importance of the O-linked, fucose-based tetrasaccharide has recently been shown in the Notch receptor system. Drosophila Notch plays a role in intercellular signaling through interactions with ligands like Delta and Serrate/Jagged. These interactions are positively or negatively regulated, respectively, by the secreted protein Fringe. Moloney et al. (46) and Brückner et al. (47) have recently demonstrated that Drosophila and mammalian Fringe proteins are O-fucose-specific beta 1,3N-acetylglucosaminyltransferases that perform the first step in the synthesis of the tetrasaccharide. Importantly, this modification modulates the ligand-receptor interaction in vivo. Because TSP-1 also functions in protein-protein interactions at the cell surface (9), it may be worthwhile to search for proteins that modulate these, analogous to Fringe in the Notch system. An enzyme activity that elongates O-linked alpha -fucose to the disaccharide has been identified in Chinese hamster ovaryl cells (48). The enzyme is widespread in biology, suggesting that the disaccharide has an important biological function (36, 48).

TSP-1 has three EGF-like modules, none of which has the CXXGG(S/T)C recognition sequence. The first module, however, has the recognition sequence for O-glucosylation, CXSXPC, and O-linked disaccharide Xyl-Glc has been described in bovine platelet TSP (49).

C-Mannosylation-- Several roles for the WXXWXXW sequences in the TSRs of TSP-1 have been suggested. Fibronectin has been shown to bind to the synthetic peptide GGWSHW (50). The same peptide binds to latent TGF-beta and inhibits its activation by TSP-1 (12). By using the yeast two-hybrid system, Aho and Uitto (51) found laminin and collagen VII to bind to this region of the TSR as well. It remains to be demonstrated conclusively, however, that native TSRs from TSP-1 bind to these molecules. Therefore, any effect that C-mannosylation has on these interactions is unknown. The situation concerning heparin binding to these sequences is inconsistent. The peptide SHWSPWSS has been found to inhibit TSP-1 binding to heparin (13), and peptides containing this sequence in addition to conserved basic residues display high affinity heparin binding (52). Importantly, the two Trp residues are essential for this interaction. On the one hand, these data are supported by the observation that heparin binding to midkine, a protein that is now recognized to be a TSR homologue (53), affects the NMR resonances of the Trp residue corresponding to the second Trp in the above-mentioned peptide (54). On the other hand, recombinant TSRs, or a proteolytic fragment from TSP-1, which are both folded molecules, do not bind heparin (see Introduction). It is difficult to reconcile these results at present, but purification of the various glycoforms of recombinant TSRs identified in this paper and comparing their heparin-binding properties may resolve some of these discrepancies.

C-Mannosylation of Trp has only been documented for vertebrate tissues and cells, although the earliest evidence for hexosylation of Trp was found in a neuropeptide from stick insect (25). Previously, it has been reported that Spodoptera frugiperda cells (Sf9) or Drosophila melanogaster Schneider 2 (S2) cells do not C-mannosylate RNase 2 (23). For S2 cells, these findings were confirmed by the results obtained with TSR123. However, Sf9 cells, and in addition Trichoplusia ni cells (High-Five), did C-mannosylate TSRs (Fig. 4). The reason for this difference remains unclear. The only relevant distinction between the two studies may be the use of different secretion signals. Nevertheless, our results show conclusively that insects are capable of C-mannosylation and that the modification is widespread in the animal kingdom.

Not all TSRs have the same C-mannosylation pattern. In TSP-1 the first Trp in the sequence WXXWXXWXXC is only modified in TSR2 (Fig. 4). Furthermore, the third Trp in this sequence in properdin, and the terminal components of complement are modified in 8 out of 9 cases (21, 22). This led to the hypothesis that an additional signal, different from the sequence WXXW, is present in these proteins (22). In contrast, in TSP-1 the third Trp was never C-mannosylated (Fig. 4). Either the TSRs in these proteins differ structurally or megakaryocytes, the site of synthesis of platelet TSP-1, are unable to perform this kind of C-mannosylation.

C- and O-glycosylations of platelet TSP-1 were stoichiometric in TSRs1 and -2, whereas the degree of modification was higher than 90% in TSR3. In contrast, recombinant modules were generally modified less, and consequently were heterogeneous in mass (Fig. 4). O-Fucosylation of TSR1 and -2 in TSR123-S2 was much lower than in TSP-1, and in all three modules elongation with hexose was completely absent. It is possible that Schneider 2 cells do not contain the glucosyltransferase, although the activity has been reported recently to occur in Drosophila (36). The level of C-mannosylation in TSR123-H5 was different for different residues, and always lower than in platelet TSP-1 (Fig. 4). Modification of Trp-480 in TSR123-H5 was also lower compared with TSR3-H5, which itself was less C-mannosylated than platelet TSP-1. These differences may result from overexpression of these proteins in the High-Five cells, if the amount of C-mannosyltransferase or dolichyl-P-Man were limiting. This would agree with the 5-fold higher level of expression of TSR123-H5 compared with TSR3-H5.4

N-Glycosylation and mucin-type O-glycosylation of recombinant proteins in Sf9 and High-Five cells has recently been reviewed (55, 56), and a direct comparison of these cells has been made (57). In contrast, nothing was known about O-linked fucose and its elongation in these cells. Given the good expression of TSRs in insect cells and the large number of biologically interesting proteins that contain these modules, further studies on these glycosylation reactions in this type of cells seem warranted.


    ACKNOWLEDGEMENTS

We thank Renate Matthies for help with amino acid sequencing and Drs. Tim Smilda and Anne Gonzalez for reading the manuscript. The ESI-quadrupole time-of-flight instrument was purchased with a grant from the "Hochschulbauförderungsgesetz" of the University of Münster (to J. P. K.).


    FOOTNOTES

* This work was supported in part by the Novartis Research Foundation (to J. H.) and by NHLBI Grants HL54462 (to D. F. M.) and HL28749 (to J. L.) from the National Institutes of Health.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Friedrich Miescher-Institut, P. O. Box 2543, CH-4002 Basel, Switzerland. Tel.: 41 61 697 4722; Fax: 41 61 697 3976; E-mail: hofsteen@fmi.ch.

|| Supported by the Interdisciplinary Center for Clinical Research, University of Münster.

Published, JBC Papers in Press, November 6, 2000, DOI 10.1074/jbc.M008073200

2 B. Macek, J. Hofsteenge and J. Peter-Katalinic, manuscript in preparation.

3 S. Hartmann and J. Hofsteenge, unpublished results.

4 K. G. Huwiler and D. F. Mosher, manuscript in preparation.


    ABBREVIATIONS

The abbreviations used are: TSP, thrombospondin; Cam, carboxamidomethyl; CID, collision-induced dissociation; CPase, carboxypeptidase; dHex, deoxyhexosyl; ESIMS, electrospray ionization mass spectrometry; Hex, hexosyl; HPAE-PAD, high pH anion exchange chromatography with pulsed amperometric detection; LC, liquid chromatography; PTH, phenylthiohydantoin; TSR, TSP type 1 repeat; HPLC, high pressure liquid chromatography; TGF-beta , transforming growth factor-beta ; EGF, epidermal growth factor.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES


1. Lawler, J. W., Slayter, H. S., and Coligan, J. E. (1978) J. Biol. Chem. 253, 8609-8616[Abstract]
2. Lawler, J., and Hynes, R. O. (1986) J. Cell Biol. 74, 2022-2027
3. Adams, J., and Lawler, J. (1993) Curr. Biol. 3, 188-190
4. Legrand, C. T., Thibert, V., Dubernard, V., Begault, B., and Lawler, J. W. (1992) Blood 79, 1995-2003[Abstract]
5. Bale, M. D. (1987) Semin. Thromb. Hemostasis 13, 326-334[Medline] [Order article via Infotrieve]
6. Bale, M. D., and Mosher, D. F. (1986) J. Biol. Chem. 261, 862-868[Abstract/Free Full Text]
7. Silverstein, R. L., and Nachman, R. L. (1987) Semin. Thromb. Hemostasis 13, 335-342[Medline] [Order article via Infotrieve]
8. Frazier, W. A. (1991) Curr. Opin. Cell Biol. 3, 792-799[Medline] [Order article via Infotrieve]
9. Adams, J. C., and Tucker, R. P. (2000) Dev. Dyn. 218, 280-299[CrossRef][Medline] [Order article via Infotrieve]
10. Mosher, D. F. (1990) Annu. Rev. Med. 41, 85-97[CrossRef][Medline] [Order article via Infotrieve]
11. Roberts, D. D. (1996) FASEB J. 10, 1183-1191[Abstract/Free Full Text]
12. Schultz-Cherry, S., Chen, H., Mosher, D. F., Misenheimer, T. M., Krutzsch, H. C., Roberts, D. D., and Murphy-Ulrich, J. E. (1995) J. Biol. Chem. 270, 7304-7310[Abstract/Free Full Text]
13. Guo, N., Krutzsch, H. C., Negre, E., Vogel, T., Blake, D. A., and Roberts, D. D. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 3040-3044[Abstract]
14. Dixit, V. M., Grant, G. A., Santaro, S. A., and Frazier, W. A. (1984) J. Biol. Chem. 259, 10100-10105[Abstract/Free Full Text]
15. Panetti, T. S., Kudryk, B. J., and Mosher, D. F. (1999) J. Biol. Chem. 274, 430-437[Abstract/Free Full Text]
16. Tuszynski, G. P., Rothman, V. L., Deutch, A. H., Hamilton, B. K., and Eyal, J. (1992) J. Cell Biol. 116, 209-217[Abstract]
17. Prater, C. A., Plotkin, J., Jaye, D., and Frazier, W. A. (1991) J. Cell Biol. 112, 1031-1040[Abstract]
18. Asch, A. S., Silbiger, S., Heimer, E., and Nachman, R. L. (1992) Biochem. Biophys. Res. Commun. 182, 1208-1217[Medline] [Order article via Infotrieve]
19. Oquendo, P., Hundt, E., Lawler, J., and Seed, B. (1989) Cell 58, 95-101[Medline] [Order article via Infotrieve]
20. Doucey, M.-A., Hess, D., Cacan, R., and Hofsteenge, J. (1998) Mol. Biol. Cell 9, 291-300[Abstract/Free Full Text]
21. Hartmann, S., and Hofsteenge, J. (2000) J. Biol. Chem. 275, 28569-28574[Abstract/Free Full Text]
22. Hofsteenge, J., Blommers, M. M., Hess, D., Furmanek, A., and Miroshnichenko, O. (1999) J. Biol. Chem. 274, 32786-32794[Abstract/Free Full Text]
23. Krieg, J., Gläsner, W., Vincentini, A., Doucey, M.-A., Löffler, A., Hess, D., and Hofsteenge, J. (1997) J. Biol. Chem. 272, 26687-26692[Abstract/Free Full Text]
24. Doucey, M.-A. (1998) la C-Mannosylation du Tryptophan: un nouveau type de glycosylation des proteines. Doctoral dissertation , Université Louis Pasteur de Strassbourg
25. Gäde, G., Keller, R., Rinehart, K. L., and Proefke, M. L. (1992) Biochem. Biophys. Res. Commun. 189, 1303-1309[Medline] [Order article via Infotrieve]
26. Adams, J. C., and Lawler, J. (1994) Mol. Biol. Cell 5, 423-437[Abstract]
27. Misenheimer, T. M., Huwiler, K. G., Annis, D. S., and Mosher, D. F. (2000) J. Biol. Chem. 275, 40938-4094[Abstract/Free Full Text]
28. Krieg, J., Hartmann, S., Vicentini, A., Gläsner, W., Hess, D., and Hofsteenge, J. (1998) Mol. Biol. Cell 9, 301-309[Abstract/Free Full Text]
29. Hofsteenge, J., Müller, D. R., de Beer, T., Löffler, A., Richter, W. J., and Vliegenthart, J. F. G. (1994) Biochemistry 33, 13524-13530[Medline] [Order article via Infotrieve]
30. Doucey, M.-A., Hess, D., Blommers, M. J., and Hofsteenge, J. (1999) Glycobiology 9, 435-441[Abstract/Free Full Text]
31. Greis, K. D., Hayes, B. K., Comer, F. I., Kirk, M., Barnes, S., Lowary, T. L., and Hart, G. W. (1996) Anal. Biochem. 234, 38-49[CrossRef][Medline] [Order article via Infotrieve]
32. Alving, K., Paulsen, H., and Peter-Katalinic, J. (1999) J. Mass Spectrom. 34, 395-407[CrossRef][Medline] [Order article via Infotrieve]
33. Rich, K. A., George, F. W., Law, J. L., and Martin, W. J. (1990) Science 249, 1574-1577[Medline] [Order article via Infotrieve]
34. Dawson, D. W., Pearce, F. A., Yhong, R., Silverstein, R. L., and Frazier, W. A. (1997) J. Cell Biol. 138, 707-717[Free Full Text]
35. Jimenez, B., Volpert, O. V., Crawford, S. E., Febbraio, M., Silverstein, R. L., and Bouck, N. (2000) Nat. Med. 6, 41-48[CrossRef][Medline] [Order article via Infotrieve]
36. Moloney, D. J., Shair, L. H., Lu, F. M., Xia, J., Locke, R., Matta, K., and Haltiwanger, R. S. (2000) J. Biol. Chem. 275, 9604-9611[Abstract/Free Full Text]
37. Nakakura, N., Hietter, H., van Dorselaer, A., and Luu, B. (1992) Eur. J. Biochem. 204, 147-153[Abstract]
38. Moloney, D. J., Lin, A. I., and Haltiwanger, R. S. (1997) J. Biol. Chem. 272, 19046-19050[Abstract/Free Full Text]
39. Klinger, M. M., Laine, R. A., and Steiner, S. M. (1981) J. Biol. Chem. 256, 7932-7938[Abstract/Free Full Text]
40. Hallgren, P., Lundblad, A., and Svensson, S. (1975) J. Biol. Chem. 250, 5312-5314[Abstract]
41. Harris, R. J., and Spellman, M. W. (1993) Glycobiology 3, 219-224[Abstract]
42. Wang, Y., and Spellman, M. W. (1998) J. Biol. Chem. 273, 8112-8118[Abstract/Free Full Text]
43. Harris, R. J., van Halbeek, H., Glushka, J., Basa, L. J., Ling, V. T., Smith, K. J., and Spellman, M. W. (1993) Biochemistry 32, 6539-6547[Medline] [Order article via Infotrieve]
44. Nishimura, H., Takao, T., Hase, S., Shimonishi, Y., and Iwanaga, S. (1992) J. Biol. Chem. 267, 17520-17525[Abstract/Free Full Text]
45. Baranski, T. J., Koelsch, G., Hartsuck, J. A., and Kornfeld, S. (1991) J. Biol. Chem. 266, 23365-23372[Abstract/Free Full Text]
46. Moloney, D. J., Panin, V. M., Johnston, S. H., Chen, J., Shao, L., Wislon, R., Wang, Y., Stanley, P., Irvine, K. D., Haltiwanger, R. S., and Vogt, T. F. (2000) Nature 406, 369-375[CrossRef][Medline] [Order article via Infotrieve]
47. Brückner, K., Perez, L., Clausen, H., and Cohen, S. (2000) Nature 406, 411-415[CrossRef][Medline] [Order article via Infotrieve]
48. Moloney, D. J., and Haltiwanger, R. S. (1999) Glycobiology 9, 679-687[Abstract/Free Full Text]
49. Nishimura, H., Yamashita, S., Zeng, Z., Walz, D. A., and Iwanaga, S. (1992) J. Biochem. (Tokyo) 111, 460-464[Abstract]
50. Sipes, J. M., Guo, N., Nègre, E., Vogel, T., Krutzsch, H. C., and Roberts, D. D. (1993) J. Cell Biol. 121, 469-477[Abstract]
51. Aho, S., and Uitto, J. (1998) Matrix Biol. 17, 401-412[CrossRef][Medline] [Order article via Infotrieve]
52. Guo, N., Krutzsch, H. C., Nègre, E., Zabrenetzky, V. S., and Roberts, D. D. (1992) J. Biol. Chem. 267, 19349-19355[Abstract/Free Full Text]
53. Kilpeläinen, I., Kaksonen, M., Kinnunen, T., Avikainen, H., Fath, M., Linhardt, R., Raulo, E., and Rauvala, H. (2000) J. Biol. Chem. 275, 13564-13570[Abstract/Free Full Text]
54. Iwasaki, W., Nagata, K., Hatanaka, H., Inui, T., Kimura, T., Muramatsu, T., Yoshida, K., Tasumi, M., and Inagaki, F. (1997) EMBO J. 16, 6936-6946[Abstract/Free Full Text]
55. Altmann, F., Staudacher, E., Wilson, I. B., and Marz, L. (1999) Glycoconj. J. 16, 109-123[Medline] [Order article via Infotrieve]
56. Lopez, M., Tetaert, D., Juliant, S., Gazon, M., Cerutti, M., Verbert, A., and Delannoy, P. (1999) Biochim. Biophys. Acta 1427, 49-61[Medline] [Order article via Infotrieve]
57. Rudd, P. M., Downing, A. K., Cadene, M., Harvey, D. J., Wormald, M. R., Weir, I., Dwek, R. A., Rifkin, D. B., and Gleizes, P. E. (2000) Biochemistry 39, 1596-1603[CrossRef][Medline] [Order article via Infotrieve]
58. Kentzer, E. J., Buko, A. M., Menon, G., and Sarin, V. K. (1990) Biochem. Biophys. Res. Commun. 171, 401-406[Medline] [Order article via Infotrieve]
59. Harris, R. D., Leonard, C. K., Guzzeta, A. W., and Spellman, M. W. (1991) Biochemistry 30, 2311-2314[Medline] [Order article via Infotrieve]
60. Bjoern, S., Foster, D. C., Thim, L., Wiberg, F. C., Christensen, M., Komiyama, Y., Pedersen, A. H., and Kisiel, W. (1991) J. Biol. Chem. 266, 11051-11057[Abstract/Free Full Text]
61. Harris, R. J., Ling, V. T., and Spellman, M. W. (1992) J. Biol. Chem. 267, 5102-5107[Abstract/Free Full Text]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.